Search

Displaying results 171 - 180 of 6970 in total
  1. Drug

    Elosulfase alfa

    go.drugbank.com/drugs/DB09051
    ApprovedInvestigational

    It was approved by the FDA in 2014 for the treatment of Morquio syndrome. Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizim™.

    Products: Vimizim 1mg/ml Concentrate for Solution for Infusion
  2. Drug

    Siltuximab

    go.drugbank.com/drugs/DB09036
    ApprovedInvestigational

    Its use is indicated for the treatment of adult patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.

    Products: Sylvant 400mg Powder for Concentrate for Solution for Infusion, Sylvant 100mg Powder for Concentrate for Solution for Infusion
  3. Drug

    Idarucizumab

    go.drugbank.com/drugs/DB09264
    Approved

    Approved under the tradename Praxbind (FDA), idarucizumab is indicated for the emergency treatment of dabigatran-associated bleeding in life-threatening or surgically induced situations.

    Products: PRAXBIND SOLUTION FOR INJECTION/INFUSION 50 MG/ML, PRAXBIND Solution for Injection/Infusion 50 mg/ml
  4. Drug

    Mosunetuzumab

    go.drugbank.com/drugs/DB15434
    ApprovedInvestigational

    [L44562] and in December 2025, the subcutaneous formulation was approved for the same indication. [L54848] … [A249320] The standard of care for patients with B-cell lymphoma includes an anti-CD20 monoclonal antibody, such as [rituximab], in combination with chemotherapy.

    Products: Lunsumio 1mg/ml Concentrate for Solution for Infusion
  5. Drug

    Ofatumumab

    go.drugbank.com/drugs/DB06650
    ApprovedInvestigational

    In February 2020, FDA and EMA approved Supplemental Biologics License Application (sBLA) and Marketing Authorization Application (MAA), respectively, for ofatumumab for the treatment of RMS in adults. … [A6921] Ofatumumab is available for intravenous administration and is marketed as Arzerra.

    Products: KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED PEN 20MG/0.4ML, KESIMPTA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 20MG/0.4ML
  6. Drug

    Fludarabine

    go.drugbank.com/drugs/DB01073
    ApprovedInvestigational

    Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

    Products: FLUDARABINE PHOSPHATE POWDER FOR SOLUTION FOR INJECTION/ INFUSION USP, Fludarabine Kabi 50mg Lyophilized Powder for Solution for Injection or Infusion
  7. Drug

    Tocilizumab

    go.drugbank.com/drugs/DB06273
    ApprovedInvestigational

    Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions.

    Categories: Biologics for Rheumatoid Arthritis Treatment, Experimental Unapproved Treatments for COVID-19Products: Actemra Concentrate for Solution for Infusion 20mg/ml, ACTEMRA 20 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION.
  8. Drug

    Azithromycin

    go.drugbank.com/drugs/DB00207
    ApprovedInvestigational

    It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. … is a part of the _azalide_ subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: Azithromycin powder for solution for injection 500mg, Zithrolide 500mg Powder for Solution for Infusion
  9. Drug

    Blinatumomab

    go.drugbank.com/drugs/DB09052
    ApprovedInvestigational

    [L44311] Full approval for this indication was granted in June 2023. … It was first approved by the FDA in December 2014 for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in relapsed and refractory patients.

    Products: BLINCYTO POWDER FOR INFUSION 35 MCG/VIAL, BLINCYTO (Blinatumomab) for injection 35 mcg/vial
  10. Drug

    Ceftriaxone

    go.drugbank.com/drugs/DB01212
    ApprovedInvestigational

    Ceftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: CYROSEF POWDER FOR SOLUTION FOR INJECTION 2GM, CYROSEF POWDER FOR SOLUTION FOR INJECTION 1GM